Form 4: Arthur A. Levin Acquires Restricted Stock Units in Stoke Therapeutics, Inc.

Director Arthur A. Levin acquired 4,842 Restricted Stock Units in Stoke Therapeutics, Inc. on March 19, 2025, vesting quarterly until December 31, 2025.

Summary

• On March 19, 2025, Arthur A. Levin, a director of Stoke Therapeutics, Inc., acquired 4,842 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Stoke Therapeutics' Common Stock upon settlement.
• The RSUs vest quarterly, with 1/4 of the total award vesting on the last day of March, June, September, and December.
• Vesting is contingent upon Levin's continued service to Stoke Therapeutics through each vesting date.
• Following the transaction, Levin directly owns 4,842 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a standard transaction of stock units to a company director. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities. This allows the public to see how company leadership is investing in the company.

Stakeholder Impact

• The acquisition of RSUs by a director can signal confidence in the company's future prospects to shareholders.

Key Dates

Keywords

Restricted Stock Units, RSU, Director, Form 4, STOK, Stoke Therapeutics, Beneficial Ownership, Acquisition